Aim­mune says US gov­ern­ment shut­down stymied its peanut al­ler­gy drug ap­pli­ca­tion

As the longest gov­ern­ment shut­down in US his­to­ry en­dures the wrath of law­mak­ers on ei­ther side of the aisle, Aim­mune Ther­a­peu­tics $AIMT will bear the brunt of stretched funds at the FDA. Com­pa­ny man­age­ment — who sub­mit­ted their ap­pli­ca­tion to mar­ket their peanut al­ler­gy drug one day pre­ced­ing the shut­down — on Mon­day said the health reg­u­la­tor had no­ti­fied them that it would not be able to re­view the ap­pli­ca­tion un­til the lapse in ap­pro­pri­a­tions ends.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER